Key result
Rotavirus is a leading cause of severe acute diarrhoea in young children worldwide, justifying the development of a live oral attenuated vaccine to be administered in the first months of life.
Why the study?
Does a live oral attenuated rotavirus vaccine prevent severe acute diarrhoea in young children?
Does a live oral attenuated rotavirus vaccine prevent severe acute diarrhoea in young children?
Rotavirus is a major cause of severe morbidity and mortality in young children globally, justifying the urgent development and implementation of live oral attenuated vaccines.
Answers are grounded in this paper and cite their sources.
Rotavirus burden supports urgent vaccine research; leaves open efficacy and safety of live oral attenuated formulations in infants.
Primary rotavirus infection in young children can cause severe acute diarrhoea requiring hospitalisation for treatment of dehydration. Morbidity and mortality rates in children throughout the world are sufficient to justify the development of a vaccine. Current strategies are aimed at the development of a live oral attenuated rotavirus vaccine to be given in the first two to three months of life, preferably in association with oral poliomyelitis vaccine.
No takes yet. Share an insight, caveat, or question.
Bishop et al. (1996) conducted a review in Rotavirus infection. Rotavirus vaccine was evaluated. Rotavirus is a leading cause of severe acute diarrhoea in young children worldwide, justifying the development of a live oral attenuated vaccine to be administered in the first months of life.
Synapse has enriched 10 related papers. Consider them for comparative context: